Ca2+ influx, phosphoinositide hydrolysis, and histamine release induced by lysophosphatidylserine in mast cells.
We have previously demonstrated that snake venom phospholipases A2 (PLA2s) and mammalian PLA2s induced inflammatory processes. This effect was correlated with the activity of the enzymes and the release of lipid mediators. We have now determined the role of lysophosphatidylserine (LysoPS) as an inflammatory lipid mediator. Thus, we have studied the possibility that intracellular calcium concentration, phosphoinositide hydrolysis, and the subsequent histamine release in mast cells is due to the action of lysophosphatidylserine. Lysophosphatidylserine-stimulated release of histamine was significantly higher than release by other lysophospholipids. The contribution of increased phospholipase C activity and the intracellular Ca2+ influx were therefore examined. LysoPS increased mast cell calcium concentration, and this increment was associated with phospholipase C activation and release of inositol phosphates. The increase in intracellular calcium and histamine degranulation induced by LysoPS were inhibited by apomorphine. Pretreatment of mast cells with pertussis toxin decreased the secretagogic effect of LysoPS and compound 48/80 without modifying the effect of the ionophore A23187. These results suggest that pertussis toxin-sensitive G-protein might be involved in the mast cell degranulation produced by lysophosphatidylserine and allow the increase in phospholipase C activity, thus enhancing intracellular calcium concentration, which then induces exocytosis of histamine.
Lloret
S
S
Departamento de Ciencias Fisiológicas, Facultad de Farmacia, Universidad de Barcelona, Spain.
Moreno
J J
JJ
D000818:Animals; D001058:Apomorphine / Q000494:pharmacology; D002118:Calcium / Q000378:metabolism*; D004790:Enzyme Induction / Q000187:drug effects; D019204:GTP-Binding Proteins / Q000037:antagonists & inhibitors; D006636:Histamine Release / Q000187:drug effects*; D018836:Inflammation Mediators / Q000494:pharmacology*; D008246:Lysophospholipids / Q000494:pharmacology*; D008297:Male; D008407:Mast Cells / Q000378:metabolism*; D051379:Mice; D037342:Pertussis Toxin; D010716:Phosphatidylinositols / Q000378:metabolism*; D051381:Rats; D010738:Type C Phospholipases / Q000096:biosynthesis; D010566:Virulence Factors, Bordetella / Q000494:pharmacology
D018836:Inflammation Mediators; D008246:Lysophospholipids; D010716:Phosphatidylinositols; D010566:Virulence Factors, Bordetella; C025059:lysophosphatidylserine; D037342:Pertussis Toxin; D010738:Type C Phospholipases; D019204:GTP-Binding Proteins; D001058:Apomorphine; D002118:Calcium